Supernus Pharmaceuticals SUPN Weighted Average Exercise Price of Vested and Expected to Vest Options
Weighted Average Exercise Price of Vested and Expected to Vest Options at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice.
The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Supernus Pharmaceuticals's weighted average exercise price of vested and expected to vest options.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Supernus Pharmaceuticals's weighted average exercise price of vested and expected to vest options?
- Supernus Pharmaceuticals (SUPN) reported weighted average exercise price of vested and expected to vest options of $35.04 in Q1 2026.
- How has Supernus Pharmaceuticals's weighted average exercise price of vested and expected to vest options changed year-over-year?
- Supernus Pharmaceuticals's weighted average exercise price of vested and expected to vest options increased by 13.0% year-over-year, from $31.01 to $35.04.
- What is the long-term trend for Supernus Pharmaceuticals's weighted average exercise price of vested and expected to vest options?
- Over 2 years (2023 to 2025), Supernus Pharmaceuticals's weighted average exercise price of vested and expected to vest options has grown at a 5.7% compound annual growth rate (CAGR), from $29.20 to $32.63.